News Jazz, Roche combo cleared by FDA for lung cancer Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?
News ASCO 25: Jazz, PharmaMar reveal SCLC survival data Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.
News Ipsen charts $1.75bn course for Kartos acquisition Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.